Fishers is having a great deal of success in attracting foreign firms in the life science industry and announced Thursday morning that a Korean company is headed to our city.

List Biotherapeutics plans a $125 million facility in Fishers encompassing 110,000 square feet on 15 acres in the Fishers Life Science & Innovation Park.  List, whose parent is Genome & Company in South Korea, plans to hire 210 employees and open by the end of 2023.

Stevanato Group and INCOG Pharma are already part of the Park, located near 126th Street and Cumberland Road.

“Fishers is perfectly positioned to support List Bio’s global expansion plans,” stated Fishers Mayor Scott Fadness in a company news release. “We have the skilled workforce, infrastructure, and partnership with my administration that allows List Bio to focus on what matters: developing next-generation technology for the LBP manufacturing industry.”

As far as government incentives in the package, pending approval of the Indiana Economic Development Corporation (IEDC) board of directors, based on the company’s job creation plans, the IEDC will commit an investment in List Biotherapeutics Inc. of up to $3.15 million in the form of incentive-based tax credits. The IEDC will also offer the company up to $75,000 in conditional training grants, and up to $1,685,000 to the local community from the Industrial Development Grant Fund to support infrastructure improvements.  These tax credits are performance-based, meaning the company is eligible to claim incentives once people are hired and trained and investments are made.

The Fishers City Council will review and vote upon additional incentives during the November 15 City Council meeting, which include a 15-year personal property tax abatement and approximately 15 acres of real property.